Clinical trial
Persistence of Immune Response After Vaccination With MCC
NCT00310687 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00310687 |
|---|---|
| Title | Persistence of Immune Response After Vaccination With MCC |
| Official title | A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD… |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Vaccines Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prevention of Meningococcal Infection |
| Intervention type | Procedure |
| Interventions | BLOOD DRAW |
| Enrollment | 1,244 |
| Start date | Oct 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Apr 4, 2006 |
| Last update posted | Sep 19, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: